India approves AstraZeneca, locally-made Covid-19 vaccines
BI Report || BusinessInsider
File photo
India has authorised two Covid-19 vaccines, paving the path for a huge vaccination program to contain the coronavirus pandemic in the world’s second most populous country.
The Central Drugs Standard Control Organisation (CDSCO) on Sunday approved two vaccines developed by the Serum Institute of India (SII) and Bharat Biotech for public use, report The Hindu.
The formal approval came after a subject expert committee (SEC) of the CDSCO recommended that permission be granted “for restricted use in emergency situation in public interest.”
India’s drugs regulator gave the authorisation for the vaccines jointly developed by Oxford University and UK-based drugmaker AstraZeneca and another developed by Indian local company Bharat Biotech.
Drugs Controller General Venugopal G Somani said that both vaccines will be administered in two dosages, reports UNB.
The country’s initial immunisation plan aims to vaccinate 300 million people — health care workers, front-line staff including police and those considered vulnerable due to their age or other diseases — by August 2021.
The Serum Institute of India, the world’s largest vaccine manufacturing company, has been contracted by AstraZeneca to make a billion doses for developing nations, including India.
On Friday, Britain became the first to approve the shot.
The other vaccine known as COVAXIN is developed by Bharat Biotech in collaboration with government agencies and is based on an inactivated form of the coronavirus.
The company has completed only two of three trial phases. The third, which tests for efficacy, began in mid-November.
Early clinical studies showed that the vaccine doesn’t have any serious side effects and produces antibodies for Covid-19.
India, with nearly 1.4 billion people, is the second-worst affected by the coronavirus after the US, with over 10.3 million confirmed cases and 149,435 deaths, though its rate of infection has come down significantly from a mid-September peak.
An application for a vaccine made by Pfizer Inc is still being reviewed.